•HLA-A*1101
restriction makes this LMP2-TCR transduction therapy especially applicable to
the Chinese population
•Targeting
the LMP2 viral epitope removes concern over on-target toxicity associated with
most cell
based
therapies
•Gene
transfer approach for TCR clones enables significantly faster (48 h)
preparation of patient derived T cells
compared to alternative co-culture methods (9 weeks)